ASCO: I-Mab, Junshi's cancer combo performs best as a first-line NSCLC treatment, with signals for CD73 as a biomarker
https://www.fiercebiotech.com/clinical-data/asco-i-mabs-antibody-combo-performs-best-first-line-treatment-patient-pool-may-be
Medical Innovation Exchange @ Copywrite 2021. All Rights Reserved.